Analyst Price Targets — TLX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 15, 2025 1:11 am | — | RBC Capital | $17.00 | $9.02 | TheFly | Telix Pharmaceuticals initiated with a Sector Perform at RBC Capital |
| September 23, 2025 12:36 pm | Laura Sutcliffe | UBS | $20.00 | $10.92 | TheFly | Telix Pharmaceuticals price target lowered to $20 from $23 at UBS |
| September 10, 2025 12:22 pm | Robert Burns | H.C. Wainwright | $20.00 | $9.69 | TheFly | Telix Pharmaceuticals price target lowered to $20 from $23 at H.C. Wainwright |
Latest News for TLX
Telix Pharmaceuticals (TLX) maintains a "Buy" rating, driven by robust revenue growth and multiple late-stage oncology assets. TLX reported FY2025 revenue of $804 million, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622 million. Lead asset TLX591-Tx advances in phase 3 for mCRPC, while TLX250-Tx targets ccRCC in both monotherapy and combination trials.
MELBOURNE, Australia and INDIANAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") invites investors to join a webinar with key opinion leaders to discuss a physician's perspective on innovations in PSMA-PET/CT imaging for prostate cancer.
MELBOURNE, Australia and INDIANAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry1, defining the potential prognostic value of PSMA-PET2 imaging through artificial intelligence (AI).
Telix's revenue grew by 56% in 2025. The Australian company develops drugs that can both detect and treat cancers.
Telix Pharmaceuticals Limited (TLX) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TLX.
U.S. House Trading
No House trades found for TLX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.